| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients W NCT07282912 | Yale University | Phase 2 |
| Recruiting | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC NCT07043270 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Recruiting | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Ap NCT07262957 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 |
| Recruiting | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer NCT07081360 | Minia University | Phase 3 |
| Recruiting | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy NCT07022015 | Minia University | N/A |
| Withdrawn | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) NCT06110598 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Di NCT06497777 | National Taiwan University Hospital | — |
| Completed | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer NCT06464965 | Zhejiang Provincial People's Hospital | Phase 1 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Not Yet Recruiting | The Role of the Human Microbiome in Patients After Pancreatic Resection. NCT06381882 | St. Antonius Hospital | — |
| Recruiting | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101 NCT05984810 | Leiden University Medical Center | Phase 2 |
| Completed | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors NCT06208124 | Immuneering Corporation | Phase 1 / Phase 2 |
| Recruiting | Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX NCT06349278 | Laval University | N/A |
| Terminated | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy NCT06290856 | Oslo University Hospital | — |
| Recruiting | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis NCT06160596 | Cure 51 | — |
| Recruiting | Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer NCT06065891 | Jon Unosson | N/A |
| Recruiting | Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05825066 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) NCT05915351 | University of Kansas Medical Center | Phase 2 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors NCT05784597 | Philogen S.p.A. | Phase 1 |
| Completed | Digital Confocal Microscopy for Real-time Diagnosis of Pancreatic Solid Lesion NCT06315439 | Campus Bio-Medico University | — |
| Completed | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 NCT05518071 | Leiden University Medical Center | Phase 2 |
| Terminated | CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma NCT05325281 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Genetic Testing Decision Aid NCT05470920 | Massachusetts General Hospital | N/A |
| Completed | Patient-derived Organoids Drug Screen in Pancreatic Cancer NCT05351983 | Prof. Dr. med. Dres. h.c. Jan Schmidt, MME | N/A |
| Recruiting | Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma NCT05376592 | Wake Forest University Health Sciences | — |
| Recruiting | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer NCT05356039 | Umeå University | — |
| Completed | Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcino NCT05340569 | Laval University | N/A |
| Withdrawn | Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids NCT04821219 | Mayo Clinic | N/A |
| Completed | A Proof-of-Concept Study Evaluating LINFU™ NCT05161013 | Adenocyte, LLC | N/A |
| Active Not Recruiting | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma NCT04331041 | Washington University School of Medicine | Phase 2 |
| Completed | A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma NCT06277206 | Zhejiang University | — |
| Recruiting | Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma NCT04998552 | Capital Health System, Inc | N/A |
| Completed | 18F-FAPI PET Imaging in Pancreatic Adenocarcinoma NCT05884463 | Zhejiang University | N/A |
| Unknown | Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer NCT04636788 | Huazhong University of Science and Technology | N/A |
| Completed | PRECISE: Pancreatic Cancer and Exercise NCT04305067 | Queen's University, Belfast | N/A |
| Unknown | Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples NCT05571956 | Ajou University School of Medicine | N/A |
| Unknown | Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial) NCT04435067 | IRCCS San Raffaele | — |
| Recruiting | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy NCT04571294 | Humanitas Hospital, Italy | N/A |
| Unknown | Analysis Of The Anxiety-Depressive Pattern, Quality Of Life And Assessment Of Personality in Patients With Pan NCT04396093 | Michele Reni | — |
| Withdrawn | The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and NCT04045730 | Yale University | Phase 2 |
| Unknown | The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly NCT04164602 | University of Pecs | — |
| Recruiting | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancrea NCT03492671 | Loma Linda University | Phase 2 |
| Recruiting | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer NCT03977233 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy NCT04241367 | National Cancer Center, Korea | — |
| Recruiting | PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma NCT04099134 | University of Ulm | — |
| Completed | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula NCT03410914 | Sunnybrook Health Sciences Centre | Phase 2 |
| Completed | Pancreatic Cancer Dietary Assessment Study NCT03616431 | The Christie NHS Foundation Trust | — |
| Unknown | The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC) NCT03472716 | Centre Leon Berard | — |
| Completed | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Ade NCT03377491 | NovoCure Ltd. | Phase 3 |
| Unknown | Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues NCT03544255 | Ying Lv | — |
| Terminated | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma NCT03822936 | CNAO National Center of Oncological Hadrontherapy | Phase 2 |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Completed | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic NCT03331562 | Translational Genomics Research Institute | Phase 2 |
| Completed | Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study) NCT03532347 | Newcastle-upon-Tyne Hospitals NHS Trust | N/A |
| Terminated | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer ( NCT02707328 | The Cooper Health System | Phase 1 |
| Recruiting | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology NCT06055010 | UMC Utrecht | — |
| Unknown | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer NCT02707315 | The Cooper Health System | EARLY_Phase 1 |
| Completed | EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration NCT01774162 | University of Alberta | N/A |
| Terminated | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma NCT01413087 | Anchiano Therapeutics Israel Ltd. | Phase 2 |
| Unknown | A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma. NCT04147403 | Shanghai Jiao Tong University School of Medicine | — |